IJCRAR is now DOI (CrossRef) registered Research Journal. The DOIs are assigned to all published IJCRAR Articles.

INDEXED IN INDEX COPERNICUS - ICI Journals Master List 2016 - IJCRAR--ICV 2016: 81.15 For more details click here

Abstract                 Volume:6  Issue-6  Year-2018          Original Research Articles


Online ISSN : 2347 - 3215
Issues : 12 per year
Publisher : Excellent Publishers
Email : editorijcret@gmail.com

Berberine Binds in Silico to Anti-cancer Drug Target Enzyme Phosphoinositide 3- Kinase (Human PI3 K) with Affinity Comparable to Known Inhibitors of the Enzyme
K.S.V. Prabhu Rathnam1,2 and C. Damaodara Reddy1*
1Sugen Life Sciences Pvt.Ltd. 4/86, S.V.Nagar Perumallapalli, Tirupathi – 517502, India
2S.V.University, Tirupathi – 517502, India
*Corresponding author
Abstract:

Phosphoinositide 3-kinase (PI3K) is an intracellular enzyme functioning as an inositol lipid kinase and is activated by several upstream growth factor receptors. PI3 K controls diverse cellular responses including but not limited to cell proliferation, survival, etc. Several recent reports have undoubtedly proved that PI3K is a druggable target and several research groups and pharmaceutical companies are developing inhibitors. In the present study, we present the results of Insilco docking analysis of a phytocompound Berberine and were compared with several known commercial PI3 K inhibitors. Our results show that Berberine docks efficiently with the active site of PI3 K and forms stable bonds with active site amino acid residues and essentially stalls enzyme activity. Our results also show that the bonding energies of these interactions are far more superior to the commercial PI3 K inhibitors and probably advocates as a probable PI3 K inhibitor.

Keywords: Berberine PI3K, Breast cancer, Triple negative, Epirubicin.
Download this article as Download

How to cite this article:

Prabhu Rathnam, K.S.V. and Damaodara Reddy, C. 2018. Berberine Binds in Silico to Anti-cancer Drug Target Enzyme Phosphoinositide 3- Kinase (Human PI3 K) with Affinity Comparable to Known Inhibitors of the Enzyme.Int.J.Curr.Res.Aca.Rev. 6(6): 16-21
doi: https://doi.org/10.20546/ijcrar.2018.606.003